The company states: “AptarGroup (ATR) announced that its Unidose Powder Nasal Spray System is being utilized in ENA Respiratory’s Phase II clinical study of INNA 051, an investigational nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections. This collaboration reflects the growing role of intranasal delivery technologies in supporting the development of novel, non-vaccine approaches to respiratory disease prevention.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATR:
- AptarGroup Announces CEO Succession and Leadership Transition Plan
- AptarGroup CEO Stephan Tanda to retire, Gael Touya to succeed
- AptarGroup: Solid Strategic Position and Structural Growth Offset by Near-Term Earnings Headwinds, Warranting a Hold Rating
- AptarGroup Earnings Call Balances Growth With Margin Strain
- AptarGroup price target raised to $147 from $142 at BofA